FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner Peptide BPC 157 Does It Work? Breaking Down the Evidence and the Hype The Human Lab Rats Injecting Themselves with Peptides Office for Science and Society McGill University In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for BPC 157 Erectile Dysfunction: Exploring the Peptide's Potential Role